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Propositions 
to uphold the thesis 
Response Assessments in Cancer Clinical Trials 
 
1. Measuring tumor lesions in two or three dimensions does not provide better 
accuracy in the assessment of tumor response than measuring one dimension 
only (this thesis)      
2. Partial response and progression criteria are based on arbitrary cut off and 
should be used carefully to guide decisions to continue or stop treatment (this 
thesis) 
3. Response rates in phase III trials are usually lower than in phase II trials 
investigating the same treatment (this thesis)  
4. Clinical response is a good indicator of anti-cancer activity but is rarely a true 
surrogate of global efficacy of cancer treatments (this thesis)  
5. Measurement of bone lesions selected as target lesions is possible within pre-
defined conditions (this thesis) 
6. RECIST are the criteria of choice to asses anti-cancer activity of treatment for 
most tumor types (this thesis) 
7. The value of  confirmation of response with a second examination some time 
after the first indication of response is limited  
8. Alternative methods of screening new anticancer agents are needed for Gastro 
Intestinal Stromal Tumors 
9. Progression is a better endpoint than response to determine the anti-tumor 
activity of new anti-cancer agents which do not behave as cytotoxic drugs  
10. In most instances progression is a more suitable endpoint than survival to 
determine the efficacy of new anti-cancer agents but should be used with 
precautions! 
11. A specialist is one who knows more and more about less and less, ultimately 
knowing everything... about nothing! 
 
 
Rotterdam, 8 June 2006 
Patrick Therasse 
   
    
